Literature DB >> 30194170

Shift of Keratin Expression Profile in End-stage Kidney Increases the Risk of Tumor Development.

Donat Peter Sarlos1, Lehel Peterfi1, Arpad Szanto1, Gyula Kovacs2,3.   

Abstract

BACKGROUND/AIM: Pre-neoplastic lesions and renal cell tumors of distinct pheno- and genotypes occur frequently in end-stage kidneys. The aim of this study was to investigate the role of KRT7 and KRT19 in this process, the expression of which was previously detected by Affymetrix GeneChip analysis. PATIENTS AND METHODS: Twelve end-stage kidneys were analyzed to find pre-neoplastic lesions and tumors and expression of KRT7 and KRT19 was examined by immunohistochemistry.
RESULTS: A total of 17 tumors, 149 pre-neoplastic lesions, 179 simple or proliferative cysts >2 mm were identified. Diffuse expression of KRT7 and KRT19 was seen in all end-stage kidneys as well as in the vast majority of cysts, pre-neoplastic lesions and tumors.
CONCLUSION: Our data indicates that de novo expression of KRT7 and KRT19 resulting in altered plasticity and stem cell characteristics of epithelial cells might be a crucial factor in increasing the risk of tumor development in end-stage kidneys. Copyright
© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  End-stage renal disease; KRT19; KRT7; immunohistochemistry; tumor development

Mesh:

Substances:

Year:  2018        PMID: 30194170     DOI: 10.21873/anticanres.12845

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  2 in total

1.  Gut commensal derived-valeric acid protects against radiation injuries.

Authors:  Yuan Li; Jiali Dong; Huiwen Xiao; Shuqin Zhang; Bin Wang; Ming Cui; Saijun Fan
Journal:  Gut Microbes       Date:  2020-01-13

2.  Dual role of KRT17: development of papillary renal cell tumor and progression of conventional renal cell carcinoma.

Authors:  Donat Peter Sarlos; Maria V Yusenko; Lehel Peterfi; Arpad Szanto; Gyula Kovacs
Journal:  J Cancer       Date:  2019-08-28       Impact factor: 4.207

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.